Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros

Bases de dados
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
Bioconjug Chem ; 35(5): 682-692, 2024 May 15.
Artigo em Inglês | MEDLINE | ID: mdl-38648296

RESUMO

The delivery of proteins into the cytosol holds great promise for cell signaling manipulation and the development of precision medicine. However, this potency is challenged by achieving targeted and controlled delivery, specifically within diseased cells. In this study, we introduce a versatile and effective method for the precision delivery of therapeutic proteins to cancer cells by designing polyphenol-assisted biomineralization of zeolite imidazole framework-8 (ZIF-8). We demonstrate that by leveraging the strong noncovalent binding affinity of epigallocatechin gallate (EGCG) with both proteins and ZIF-8, our approach significantly enhances the biomineralization of ZIF-8, which in turn improves the efficiency of protein encapsulation and intracellular delivery. Moreover, the incorporation of EGCG within ZIF-8 enables controlled degradation of the nanoparticles and the selective release of the encapsulated proteins in cancer cells. This selective release is triggered by the oxidation of EGCG in response to the high levels of reactive oxygen species (ROS) found within cancer cells that destabilize the EGCG/ZIF-8 nanoparticles. We have further demonstrated the ability of EGCG/ZIF-8 to deliver a wide range of proteins into cancer cells, including bacterial virulence protein, to rewire cell signaling and prohibit tumor cell growth in a mouse xenograft model. Our strategy and findings underscore the potential of designing the EGCG/ZIF-8 interface for specific and controlled protein delivery for targeted cancer therapy.


Assuntos
Catequina , Estruturas Metalorgânicas , Nanopartículas , Polifenóis , Humanos , Estruturas Metalorgânicas/química , Polifenóis/química , Polifenóis/farmacologia , Animais , Nanopartículas/química , Catequina/análogos & derivados , Catequina/química , Catequina/administração & dosagem , Catequina/farmacologia , Camundongos , Zeolitas/química , Biomineralização , Imidazóis/química , Linhagem Celular Tumoral , Neoplasias/tratamento farmacológico , Neoplasias/metabolismo , Sistemas de Liberação de Medicamentos/métodos , Espécies Reativas de Oxigênio/metabolismo
2.
Chembiochem ; 24(19): e202300413, 2023 10 04.
Artigo em Inglês | MEDLINE | ID: mdl-37496112

RESUMO

PROTACs (Proteolysis-Targeting Chimeras) have emerged as a groundbreaking class of chemical tools that facilitate the degradation of target proteins by leveraging the ubiquitin-proteasome system (UPS). However, the effective utilization of PROTACs in chemical biology studies and therapeutics encounters significant challenges when it comes to achieving cell-selective protein degradation and in vivo applications. This review article aims to shed light on recent advancements in the development of Pro-PROTACs, which exhibit controlled protein degradation capabilities in response to external stimuli or disease-related endogenous biochemical signals. The article delves into the specific chemical strategies employed to regulate the interaction between PROTACs and E3 ubiquitin ligases or target proteins. These strategies enable spatial and temporal control over the protein degradation potential of Pro-PROTACs. Furthermore, the review summarizes recent investigations regarding the delivery of PROTACs using biodegradable nanoparticles for in vivo applications and targeted protein degradation. Such delivery systems hold great promise for enabling efficient and selective protein degradation in vivo. Lastly, the article provides a perspective on the future design of multifunctional PROTACs and their intracellular delivery mechanisms, with a particular focus on achieving cell-selective protein degradation.


Assuntos
Complexo de Endopeptidases do Proteassoma , Quimera de Direcionamento de Proteólise , Proteólise , Complexo de Endopeptidases do Proteassoma/metabolismo , Ubiquitina-Proteína Ligases/metabolismo , Proteínas/metabolismo , Ubiquitinas/metabolismo
3.
Angew Chem Int Ed Engl ; 61(39): e202206277, 2022 09 26.
Artigo em Inglês | MEDLINE | ID: mdl-35924720

RESUMO

Ferroptosis is a new form of regulated, non-apoptotic cell death driven by iron-dependent phospholipid peroxidation. Its therapeutic potential is however, greatly limited by the low efficiency of regulating cell ferroptosis in vivo. Herein, we report a PROTAC-based protein degrader that depletes endogenous glutathione peroxidase 4 (GPX4) and induces cancer cell ferroptosis. We demonstrate that a rationally designed GPX4 degrader, dGPX4, can deplete tumor cell GPX4 via proteasomal protein degradation, showing a five-fold enhancement of ferroptosis induction efficiency compared to that of GPX4 inhibition using ML162. Moreover, we show that the intracellular delivery of dGPX4 using biodegradable lipid nanoparticles (dGPX4@401-TK-12) induces cell-selective ferroptosis by targeting cancer cell microenvironment. The in vivo administration of dGPX4@401-TK-12 effectively suppresses tumor growth without appreciable side effects. We anticipate the protein degradation strategy described herein could be easily expanded to other essential regulatory proteins of ferroptosis for developing targeted cancer therapeutics.


Assuntos
Ferroptose , Neoplasias , Glutationa/metabolismo , Glutationa Peroxidase/metabolismo , Humanos , Ferro/metabolismo , Peroxidação de Lipídeos , Lipossomos , Nanopartículas , Fosfolipídeo Hidroperóxido Glutationa Peroxidase , Fosfolipídeos , Microambiente Tumoral
4.
Angew Chem Int Ed Engl ; 60(16): 8596-8606, 2021 04 12.
Artigo em Inglês | MEDLINE | ID: mdl-32385892

RESUMO

Recent innovations in genome editing have enabled the precise manipulation of the genetic information of mammalians, and benefitted the development of next-generation gene therapy. Despite these advances, several barriers to the clinical translation of genome editing remain, including the intracellular delivery of genome editing machinery, and the risk of off-target editing effect. Here, we review the recent advance of spatiotemporal delivery of CRISPR/Cas9 genome editing machinery, which is composed of programmable Cas9 nuclease and a single-guide RNA (sgRNA) using stimuli-responsive nanoparticles. We discuss the specific chemistries that have been used for controlled Cas9/sgRNA delivery and intracellular release in the presence of endogenous or external signals. These methodologies can leverage biological signals found locally within disease cells, or exogenous signals administrated with spatiotemporal control, through which an improved genome editing could be achieved. We also discuss the future in exploiting these approaches for fundamental biomedical applications and therapeutic genome editing.


Assuntos
Proteína 9 Associada à CRISPR/genética , Sistemas CRISPR-Cas/genética , Edição de Genes , Técnicas de Transferência de Genes , Animais , Humanos
5.
Angew Chem Int Ed Engl ; 60(10): 5429-5435, 2021 03 01.
Artigo em Inglês | MEDLINE | ID: mdl-33247547

RESUMO

Hierarchical self-assembly (HAS) is a powerful approach to create supramolecular nanostructures for biomedical applications. This potency, however, is generally challenged by the difficulty of controlling the HAS of biomacromolecules and the functionality of resulted HAS nanostructures. Herein, we report a modular approach for controlling the HAS of discrete metal-organic cages (MOC) into supramolecular nanoparticles, and its potential for intracellular protein delivery and cell-fate specification. The hierarchical coordination-driven self-assembly of adamantane-functionalized M12 L24 MOC (Ada-MOC) and the host-guest interaction of Ada-MOC with ß-cyclodextrin-conjugated polyethylenimine (PEI-ßCD) afford supramolecular nanoparticles in a controllable manner. HAS maintains high efficiency and orthogonality in the presence of protein, enabling the encapsulation of protein into the nanoparticles for intracellular protein delivery for therapeutic application and CRISPR/Cas9 genome editing.


Assuntos
Portadores de Fármacos/química , Estruturas Metalorgânicas/química , Nanopartículas/química , Adamantano/análogos & derivados , Adamantano/metabolismo , Antineoplásicos/metabolismo , Antineoplásicos/farmacologia , Proteína 9 Associada à CRISPR/genética , Proteína 9 Associada à CRISPR/metabolismo , Portadores de Fármacos/síntese química , Portadores de Fármacos/metabolismo , Endocitose/fisiologia , Edição de Genes/métodos , Genoma Humano , Proteínas de Fluorescência Verde/genética , Proteínas de Fluorescência Verde/metabolismo , Células HEK293 , Células HeLa , Humanos , Integrases/genética , Integrases/metabolismo , Estruturas Metalorgânicas/síntese química , Estruturas Metalorgânicas/metabolismo , Nanopartículas/metabolismo , Polietilenoimina/análogos & derivados , Polietilenoimina/metabolismo , RNA Guia de Cinetoplastídeos/genética , RNA Guia de Cinetoplastídeos/metabolismo , Ribonuclease Pancreático/metabolismo , Ribonuclease Pancreático/farmacologia , Ribonucleoproteínas/genética , Ribonucleoproteínas/metabolismo , beta-Ciclodextrinas/síntese química , beta-Ciclodextrinas/química , beta-Ciclodextrinas/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA